Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.W | TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > Looked at Q3 filing on Sedar again
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(12061)
•••
Comment by ScienceFirston Apr 14, 2023 8:15am
159 Views
Post# 35394723

RE:RE:RE:RE:Looked at Q3 filing on Sedar again

RE:RE:RE:RE:Looked at Q3 filing on Sedar againN0taP00p  ... Not enough info?  Just a buzz word from you to look important.  A graduate of Bungee's kindergarden.  Just like FGPstuck. 

Funny, we have:

1) MD&A,
2) news releases regarding presence at ASCO-GU,
3) news releases regarding AUA,
4) FDA Breakthrough timeline and a timeframe when they would apply,
5) Jan 3rd Biotuesday article, entereting discussions with big pharmas into 2023-2024.

You don't even know what's material or not.  So buzz off!

For the rest, your expectations are those of a clown that wouldn't divulge more if he was in the same position as TLT.  Keep playing the armchair quarterback.  It fits you well.  It shows how amateure you are.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities